{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:02:31Z","timestamp":1793325751493,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30 DK090744"],"award-info":[{"award-number":["P30 DK090744"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10157-018-1542-x","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T15:05:22Z","timestamp":1518793522000},"page":"906-916","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment"],"prefix":"10.1007","volume":"22","author":[{"given":"Yashang","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina Lehmann","family":"Blount","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan Kaufman","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie","family":"Bitterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Droher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Moeckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Karihaloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5809-9961","authenticated-orcid":false,"given":"Neera K.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,16]]},"reference":[{"key":"1542_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1056\/NEJMra022161","volume":"350","author":"PD Wilson","year":"2004","unstructured":"Wilson PD. Polycystic kidney disease. N Engl J Med 2004;350: 151\u201364.","journal-title":"N Engl J Med"},{"key":"1542_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/ng0695-151","volume":"10","author":"J Hughes","year":"1995","unstructured":"Hughes J, Ward CJ, Peral B, Aspinwall R, Clark K, San Millan JL, Gamble V, Harris PC. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet 1995;10:151\u201360.","journal-title":"Nat Genet"},{"key":"1542_CR3","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","volume":"272","author":"T Mochizuki","year":"1996","unstructured":"Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, Reynolds DM, Cai Y, Gabow PA, Pierides A, Kimberling WJ, Breuning MH, Deltas CC, Peters DJ, Somlo S. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science. 1996;272:1339\u201342.","journal-title":"Science"},{"key":"1542_CR4","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1172\/JCI80467","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Zhou X, Fan LX, Yao Y, Swenson-Fields KI, Gadjeva M, Wallace DP, Peters DJ, Yu A, Grantham JJ, Li X. Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease. J Clin Invest 2015;125:2399\u2013412.","journal-title":"J Clin Invest"},{"key":"1542_CR5","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1681\/ASN.2011010084","volume":"22","author":"A Karihaloo","year":"2011","unstructured":"Karihaloo A, Koraishy F, Huen SC, Lee Y, Merrick D, Caplan MJ, Somlo S, Cantley LG. Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2011;22:1809\u201314.","journal-title":"J Am Soc Nephrol"},{"key":"1542_CR6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/ki.2012.446","volume":"83","author":"KI Swenson-Fields","year":"2013","unstructured":"Swenson-Fields KI, Vivian CJ, Salah SM, Peda JD, Davis BM, van Rooijen N, Wallace DP, Fields TA. Macrophages promote polycystic kidney disease progression. Kidney Int 2013;83:855\u201364.","journal-title":"Kidney Int"},{"key":"1542_CR7","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/ki.1991.87","volume":"39","author":"KD Gardner Jr","year":"1991","unstructured":"Gardner KD Jr, Burnside JS, Elzinga LW, Locksley RM. Cytokines in fluids from polycystic kidneys. Kidney Int 1991;39: 718\u201324.","journal-title":"Kidney Int"},{"key":"1542_CR8","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1097\/01.ASN.0000088720.61783.19","volume":"14","author":"D Zheng","year":"2003","unstructured":"Zheng D, Wolfe M, Cowley BD Jr, Wallace DP, Yamaguchi T, Grantham JJ. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2003;14:2588\u201395.","journal-title":"J Am Soc Nephrol"},{"key":"1542_CR9","doi-asserted-by":"crossref","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transpl. 2017;1\u201313.","DOI":"10.1093\/ndt\/gfx079"},{"key":"1542_CR10","unstructured":"Grantham JJ, Chapman AB, Blais J, Czerwiec FS, Devuyst O, Gansevoort RT, Higashihara E, Krasa H, Zhou W, Ouyang J, Perrone RD, Torres VE. Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrol Dial Transpl. 2017;32:969\u201375."},{"key":"1542_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1536\/ihj.54.98","volume":"54","author":"M Ishikawa","year":"2013","unstructured":"Ishikawa M, Kobayashi N, Sugiyama F, Onoda S, Ishimitsu T. Renoprotective effect of vasopressin v2 receptor antagonist tolvaptan in Dahl rats with end-stage heart failure. Int Heart J. 2013;54:98\u2013106.","journal-title":"Int Heart J"},{"key":"1542_CR12","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1161\/CIRCHEARTFAILURE.112.968750","volume":"5","author":"T Yamazaki","year":"2012","unstructured":"Yamazaki T, Izumi Y, Nakamura Y, Yamashita N, Fujiki H, Osada-Oka M, Shiota M, Hanatani A, Shimada K, Iwao H, Yoshiyama M. Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats. Circ Heart Fail. 2012;5:794\u2013802.","journal-title":"Circ Heart Fail"},{"key":"1542_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1254\/jphs.13086FP","volume":"123","author":"T Yamazaki","year":"2013","unstructured":"Yamazaki T, Nakamura Y, Shiota M, Osada-Oka M, Fujiki H, Hanatani A, Shimada K, Miura K, Yoshiyama M, Iwao H, Izumi Y. Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats. J Pharmacol Sci. 2013;123:58\u201366.","journal-title":"J Pharmacol Sci"},{"key":"1542_CR14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/FJC.0000000000000300","volume":"66","author":"T Ikeda","year":"2015","unstructured":"Ikeda T, Iwanaga Y, Watanabe H, Morooka H, Akahoshi Y, Fujiki H, Miyazaki S. Effects of long-term blockade of vasopressin receptor types 1a and 2 on cardiac and renal damage in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 2015;66: 487\u201396.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1542_CR15","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1093\/hmg\/ddp165","volume":"18","author":"X Song","year":"2009","unstructured":"Song X, Di Giovanni V, He N, Wang K, Ingram A, Rosenblum ND, Pei Y. Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum Mol Genet. 2009;18:2328\u201343.","journal-title":"Hum Mol Genet"},{"key":"1542_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2215\/CJN.04140510","volume":"6","author":"V Menon","year":"2011","unstructured":"Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M. Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6:7\u201313.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1542_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40620-014-0045-4","volume":"27","author":"I Kocyigit","year":"2014","unstructured":"Kocyigit I, Eroglu E, Orscelik O, Unal A, Gungor O, Ozturk F, Karakukcu C, Imamoglu H, Sipahioglu MH, Tokgoz B, Oymak O. Pentraxin 3 as a novel bio-marker of inflammation and endothelial dysfunction in autosomal dominant polycystic kidney disease. J Nephrol. 2014;27:181\u20136.","journal-title":"J Nephrol"},{"key":"1542_CR18","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.4049\/jimmunol.162.7.4094","volume":"162","author":"A Yamada","year":"1999","unstructured":"Yamada A, Kubo K, Takeshita T, Harashima N, Kawano K, Mine T, Sagawa K, Sugamura K, Itoh K. Molecular cloning of a glycosylphosphatidylinositol-anchored molecule CDw108. J Immunol 1999;162:4094\u2013100.","journal-title":"J Immunol"},{"key":"1542_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s12026-013-8460-5","volume":"57","author":"R Garcia-Areas","year":"2013","unstructured":"Garcia-Areas R, Libreros S, Iragavarapu-Charyulu V. Semaphorin7A: branching beyond axonal guidance and into immunity. Immunol Res 2013;57:81\u20135.","journal-title":"Immunol Res"},{"key":"1542_CR20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nature01790","volume":"424","author":"RJ Pasterkamp","year":"2003","unstructured":"Pasterkamp RJ, Peschon JJ, Spriggs MK, Kolodkin AL. Semaphorin 7A promotes axon outgrowth through integrins and MAPKs. Nature. 2003;424:398\u2013405.","journal-title":"Nature"},{"key":"1542_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1042\/BC20040103","volume":"97","author":"G Delorme","year":"2005","unstructured":"Delorme G, Saltel F, Bonnelye E, Jurdic P, Machuca-Gayet I. Expression and function of semaphorin 7A in bone cells. Biol Cell 2005;97:589\u201397.","journal-title":"Biol Cell"},{"key":"1542_CR22","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1084\/jem.20061273","volume":"204","author":"HR Kang","year":"2007","unstructured":"Kang HR, Lee CG, Homer RJ, Elias JA. Semaphorin 7A plays a critical role in TGF-beta1-induced pulmonary fibrosis. J Exp Med. 2007;204:1083\u201393.","journal-title":"J Exp Med"},{"key":"1542_CR23","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/nature05652","volume":"446","author":"K Suzuki","year":"2007","unstructured":"Suzuki K, Okuno T, Yamamoto M, Pasterkamp RJ, Takegahara N, Takamatsu H, Kitao T, Takagi J, Rennert PD, Kolodkin AL, Kumanogoh A, Kikutani H. Semaphorin 7A initiates T-cell-mediated inflammatory responses through alpha1beta1 integrin. Nature. 2007;446:680\u20134.","journal-title":"Nature"},{"key":"1542_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1164\/rccm.201206-1109OC","volume":"187","author":"RA Reilkoff","year":"2013","unstructured":"Reilkoff RA, Peng H, Murray LA, Peng X, Russell T, Montgomery R, Feghali-Bostwick C, Shaw A, Homer RJ, Gulati M, Mathur A, Elias JA, Herzog EL. Semaphorin 7a + regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-beta1-induced pulmonary fibrosis. Am J Respir Crit Care Med. 2013;187:180\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"1542_CR25","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1002\/art.30386","volume":"63","author":"Y Gan","year":"2011","unstructured":"Gan Y, Reilkoff R, Peng X, Russell T, Chen Q, Mathai SK, Homer R, Gulati M, Siner J, Elias J, Bucala R, Herzog E. Role of semaphorin 7a signaling in transforming growth factor \u03b21\u2013induced lung fibrosis and scleroderma-related interstitial lung disease. Arthritis Rheum. 2011;63:2484\u201394.","journal-title":"Arthritis Rheum"},{"key":"1542_CR26","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ajpath.2013.05.030","volume":"183","author":"S De Minicis","year":"2013","unstructured":"De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Trozzi L, Candelaresi C, Bataller R, Millan C, Brenner DA, Vivarelli M, Mocchegiani F, Marzioni M, Benedetti A, Svegliati-Baroni G. Semaphorin 7A contributes to TGF-beta-mediated liver fibrogenesis. The Am J Pathol 2013;183:820\u201330.","journal-title":"The Am J Pathol"},{"key":"1542_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nrneph.2011.109","volume":"7","author":"JJ Grantham","year":"2011","unstructured":"Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2011;7:556\u201366.","journal-title":"Nat Rev Nephrol"},{"key":"1542_CR28","doi-asserted-by":"publisher","first-page":"F459-F472","DOI":"10.1152\/ajprenal.00146.2014","volume":"308","author":"A Yuan","year":"2015","unstructured":"Yuan A, Lee Y, Choi U, Moeckel G, Karihaloo A. Chemokine receptor Cxcr4 contributes to kidney fibrosis via multiple effectors. Am J Physiol Renal Physiol. 2015;308:F459\u201372.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1542_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1681\/ASN.2008050507","volume":"20","author":"Y Pei","year":"2009","unstructured":"Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, Parfrey P, Cramer B, Coto E, Torra R, San Millan JL, Gibson R, Breuning M, Peters D, Ravine D. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009;20: 205\u201312.","journal-title":"J Am Soc Nephrol"},{"key":"1542_CR30","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930\u201342.","journal-title":"N Engl J Med"},{"key":"1542_CR31","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1053\/j.ajkd.2014.11.010","volume":"65","author":"WE Boertien","year":"2015","unstructured":"Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT. Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function. Am J Kidney Dis 2015;65:833\u201341.","journal-title":"Am J Kidney Dis"},{"key":"1542_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/sj.ki.5002627","volume":"73","author":"M Mrug","year":"2008","unstructured":"Mrug M, Zhou J, Woo Y, Cui X, Szalai AJ, Novak J, Churchill GA, Guay-Woodford LM. Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. Kidney Int. 2008;73:63\u201376.","journal-title":"Kidney Int"},{"key":"1542_CR33","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.bbadis.2011.06.012","volume":"1812","author":"J Norman","year":"2011","unstructured":"Norman J. Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD). Biochim Biophys Acta. 2011;1812:1327\u201336.","journal-title":"Biochim Biophys Acta"},{"key":"1542_CR34","first-page":"183","volume":"30","author":"Q Cao","year":"2015","unstructured":"Cao Q, Harris DC, Wang Y. Macrophages in kidney injury, inflammation, and fibrosis. Physiology (Bethesda) 2015;30: 183\u201394.","journal-title":"Physiology (Bethesda)"},{"key":"1542_CR35","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1038\/ki.1992.413","volume":"42","author":"M Zeier","year":"1992","unstructured":"Zeier M, Fehrenbach P, Geberth S, Mohring K, Waldherr R, Ritz E. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int. 1992;42:1259\u201365.","journal-title":"Kidney Int"},{"key":"1542_CR36","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1100\/tsw.2007.274","volume":"7","author":"S Ibrahim","year":"2007","unstructured":"Ibrahim S. Increased apoptosis and proliferative capacity are early events in cyst formation in autosomal-dominant, polycystic kidney disease. Sci World J. 2007;7:1757\u201367.","journal-title":"Sci World J"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-018-1542-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1542-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-018-1542-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T01:24:49Z","timestamp":1693531489000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-018-1542-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,16]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["1542"],"URL":"https:\/\/doi.org\/10.1007\/s10157-018-1542-x","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,16]]},"assertion":[{"value":"1 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors reported the following financial supports: The study was supported by P&F from P30 DK090744 NIDDK Grant (Yale PKD Center), to NKD and AK and 1RO1 HL109233 to EH. This publication was made possible by the Yale University CTSA grant UL1TR000142 from the National Center for Advancing Translational Science (NCATS), NIH. Consultancies: NKD is a PI for one ongoing Otsuka-sponsored study investigating the role of tolvaptan in the treatment of ADPKD and has consulted for Otsuka.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted (Yale IRB approval number 1304011838) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted (IRB approval number 2012\u201310763).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}